Analyst Reco. Gritstone bio, Inc.

Equities

Delayed OTC Markets Other stock markets 11:27:48 2025-04-03 am EDT			5-day change	1st Jan Change
0.000001 ^USD	-90.00%		-.--%	-

25-04-04	Gritstone bio, Inc. Emerged from Bankruptcy	CI
25-04-03	First Amended Reorganization Plan Approved for Gritstone bio, Inc.	CI

24-10-01	B. Riley Downgrades Gritstone bio to Neutral From Buy, $1 Price Target; Shares Plummet	MT
24-10-01	HC Wainwright Downgrades Gritstone bio to Neutral From Buy, Adjusts Price Target to $0.50 From $4	MT
24-10-01	JMP Securities Downgrades Gritstone bio to Market Perform From Outperform	MT
24-05-24	B. Riley Cuts Price Target on Gritstone bio to $3 From $6, Keeps Buy Rating	MT
23-12-07	B. Riley Adjusts Gritstone bio's Price Target to $6 From $8, Keeps Buy Rating	MT
23-09-28	Piper Sandler Lifts Price Target on Gritstone bio to $7 From $6, Keeps Overweight Rating	MT
23-03-28	B. Riley Initiates Coverage of Gritstone bio With Buy Rating, Price Target of $8 Per Share	MT
22-11-07	HC Wainwright Adjusts Gritstone bio's Price Target to $7 From $12, Keeps Buy Rating	MT
22-10-31	Piper Sandler Starts Gritstone bio at Overweight With $6 Price Target	MT
22-08-22	Goldman Sachs Downgrades Gritstone bio to Sell From Neutral; Price Target is $2	MT
22-05-09	HC Wainwright Lowers Gritstone bio's Price Target to $12 From $15, Maintains Buy Rating	MT
22-03-14	HC Wainwright Adjusts Gritstone Bio's Price Target to $15 From $24, Maintains Buy Rating	MT
21-01-21	GRITSTONE ONCOLOGY : BTIG Research Adjusts Gritstone Oncology PT to $35 From $17, Maintains Buy Rating	MT
21-01-20	GRITSTONE ONCOLOGY : HC Wainwright Adjusts Gritstone Oncology's Price Target to $24 from $16, Keeps Buy Rating	MT
21-01-20	GRITSTONE ONCOLOGY : Baird Downgrades Gritstone Oncology to Underperform From Outperform; Price Target is $8	MT